Characteristic | Placebo | OROS MPH | OROS MPH |
---|---|---|---|
(n =97) | 54 mg (n= 87) | 72 mg (n =92) | |
Age, years | |||
Mean ± SD | 35.5 ± 8.8 | 35.5 ± 11.8 | 35.8 ± 10.1 |
Median (range) | 36 (18-57) | 33 (18-64) | 35 (18-60) |
Sex, n (%) | |||
Female | 45 (46.4) | 44 (50.6) | 42 (45.7) |
Male | 52 (53.6) | 43 (49.4) | 50 (54.3) |
Educational status, n (%) | |||
Primary school | 7 (7.2) | 8 (9.2) | 8 (8.7) |
Secondary school | 40 (41.2) | 24 (27.6) | 29 (31.5) |
High school | 29 (29.9) | 29 (33.3) | 26 (28.3) |
University | 21 (21.6) | 26 (29.9) | 29 (31.5) |
Age at ADHD diagnosis, years (mean ± SD) | 31.9 ± 12.8 | 31.2 ± 15.1 | 32.4 ± 13.0 |
Adult ADHD type, n (%) | |||
Combined | 73 (75.3) | 59 (67.8) | 62 (67.4) |
Predominantly inattentive | 23 (23.7) | 26 (29.9) | 28 (30.4) |
Predominantly hyperactive– impulsive | 1 (1.0) | 2 (2.3) | 2 (2.2) |
Family history of ADHD, n (%) | 53 (54.6) | 55 (63.2) | 52 (56.5) |
History of mood and anxiety disorder, n (%) | 50 (51.5) | 39 (44.8) | 39 (42.4) |
Baseline CAARS-O:SV (mean ± SD) | 36.5 ± 6.1 | 35.7 ± 6.8 | 37.3 ± 6.4 |